Browsing: life science investing
The commitment to advancing the development of bexicaserin for patients with Developmental and Epileptic Encephalopathies (DEEs) is emphasized by Dr.…
Approximately one-third of the total pharmaceutical company campaign contributions can be attributed to the top three donors: Pfizer, Merck, and…
Amgen’s Executive Vice President of Research and Development, Dr. Jay Bradner, emphasized the significance of TEPEZZA’s approval in Asia as…
“The breadth of these data showcases our strategy to advance diverse modalities for difficult-to-treat cancers,” stated Jay Bradner, M.D., executive…
At Amgen, Dr. Jay Bradner, the Executive Vice President of Research and Development and Chief Scientific Officer, emphasized the strategic…
Amgen has announced the approval of a new oral treatment option for children and adolescents with moderate to severe plaque…
Radiopharm Ventures has announced that RAD has increased its ownership stake in the company to 75%. This move demonstrates RAD’s…
CLEO, a renowned healthcare organization, has chosen several clinical trial sites located in the United States. These selected sites will…
The Phase 1a trial of SZN-043 has shown evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver.…
The Phase 1a trial of SZN-043 showed evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver. Enrollment…